Association Between Use of Dipeptidyl Peptidase-4 Inhibitors and the Risk of Acute Kidney Injury: A Nested Case-Control Study

Mayo Clinic Proceedings

Volumn 91, Issue 7, 2016, Pages 867-872

  Shih, Chia Jen ^a,b   Lee, Yi Jung ^a,c   Lo, Yuan Hao ^c   Kuo, Shu Chen ^a,c,d   Ou, Shuo Ming ^a,c   Chen, Yung Tai ^a,e  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b Deran Clinic   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e TAIPEI CITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; METFORMIN; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN; ANTIDIABETIC AGENT;

ACUTE KIDNEY FAILURE; AGE; AGED; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FOLLOW UP; HOSPITAL PATIENT; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT; SEX DIFFERENCE; URBANIZATION; ACUTE KIDNEY INJURY; DIABETES MELLITUS, TYPE 2; FACTUAL DATABASE; LONGITUDINAL STUDY; ODDS RATIO; ORAL DRUG ADMINISTRATION; TAIWAN;

ACUTE KIDNEY INJURY; ADMINISTRATION, ORAL; AGED; CASE-CONTROL STUDIES; COMORBIDITY; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LONGITUDINAL STUDIES; MALE; ODDS RATIO; RISK ASSESSMENT; TAIWAN;

EID: 84969922063     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2016.03.022     Document Type: Article

References (25)

1. 1 Nathan, D.M., Buse, J.B., Davidson, M.B., et al. American Diabetes Association, European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32:1 (2009), 193–203.
2. 2 Mauer, M., Zinman, B., Gardiner, R., et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 361:1 (2009), 40–51.
3. 3 Ou, S.M., Shih, C.J., Chao, P.W., et al. Effects on clinical outcomes of adding dipeptidyl peptidase-4 inhibitors versus sulfonylureas to metformin therapy in patients with type 2 diabetes mellitus. Ann Intern Med 163:9 (2015), 663–672.
4. 4 Green, J.B., Bethel, M.A., Armstrong, P.W., et al., TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373:3 (2015), 232–242.
5. 5 Scirica, B.M., Bhatt, D.L., Braunwald, E., et al., SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:14 (2013), 1317–1326.
6. 6 White, W.B., Cannon, C.P., Heller, S.R., et al., EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:14 (2013), 1327–1335.
7. 7 Gallwitz, B., Rosenstock, J., Rauch, T., et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 380:9840 (2012), 475–483.
8. 8 Kao, D.P., Kohrt, H.E., Kugler, J., Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. Diabet Med 25:10 (2008), 1229–1230.
9. 9 Januvia (sitagliptin) tablets label. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021995s019lbl.pdf. Accessed October 18, 2015.
10. 10 Shih, C.J., Chu, H., Chao, P.W., et al. Long-term clinical outcome of major adverse cardiac events in survivors of infective endocarditis: a nationwide population-based study. Circulation 130:19 (2014), 1684–1691.
11. 11 Chao, P.W., Shih, C.J., Lee, Y.J., et al. Association of postdischarge rehabilitation with mortality in intensive care unit survivors of sepsis. Am J Respir Crit Care Med 190:9 (2014), 1003–1011.
12. 12 Lin, C.C., Lai, M.S., Syu, C.Y., Chang, S.C., Tseng, F.Y., Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc 104:3 (2005), 157–163.
13. 13 Wu, V.C., Wu, C.H., Huang, T.M., et al., NSARG Group. Long-term risk of coronary events after AKI. J Am Soc Nephrol 25:3 (2014), 595–605.
14. 14 Cheng, C.L., Kao, Y.H., Lin, S.J., Lee, C.H., Lai, M.L., Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 20:3 (2011), 236–242.
15. 15 Lo Re, V. III, Haynes, K., Ming, E.E., et al. Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies. Pharmacoepidemiol Drug Saf 21:11 (2012), 1202–1215.
16. 16 Charlson, M.E., Pompei, P., Ales, K.L., MacKenzie, C.R., A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:5 (1987), 373–383.
17. 17 Chang, H.Y., Weiner, J.P., Richards, T.M., Bleich, S.N., Segal, J.B., Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care 18:11 (2012), 721–726.
18. 18 Chen, H.L., Hsiao, F.Y., Risk of hospitalization and healthcare cost associated with Diabetes Complication Severity Index in Taiwan's National Health Insurance Research Database. J Diabetes Complications 28:5 (2014), 612–616.
19. 19 Pendergrass, M., Fenton, C., Haffner, S.M., Chen, W., Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis. Diabetes Obes Metab 14:7 (2012), 596–600.
20. 20 Karagiannis, T., Paschos, P., Paletas, K., Matthews, D.R., Tsapas, A., Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ, 344, 2012, e1369.
21. 21 Kirino, Y., Sato, Y., Kamimoto, T., Kawazoe, K., Minakuchi, K., Nakahori, Y., Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats. J Endocrinol 200:1 (2009), 53–61.
22. 22 Kawasaki, I., Hiura, Y., Tamai, A., et al. Sitagliptin reduces the urine albumin-to-creatinine ratio in type 2 diabetes through decreasing both blood pressure and estimated glomerular filtration rate. J Diabetes 7:1 (2015), 41–46.
23. 23 Tanaka, T., Higashijima, Y., Wada, T., Nangaku, M., The potential for renoprotection with incretin-based drugs. Kidney Int 86:4 (2014), 701–711.
24. 24 Etminan, M., Pharmacoepidemiology II: the nested case-control study–a novel approach in pharmacoepidemiologic research. Pharmacotherapy 24:9 (2004), 1105–1109.
25. 25 Cooper, M.E., Perkovic, V., McGill, J.B., et al. Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes. Am J Kidney Dis 66:3 (2015), 441–449.